DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• DNA topoisomerase II targeting agents (e.g., etoposide, doxorubicin) are established chemotherapy drugs.
• Topoisomerase I inhibitors (e.g., topotecan, irinotecan) are approved for solid tumors.
• Both classes of drugs function by inducing DNA damage through their target enzymes.

Purpose of the Study:

• To review the mechanisms of action for topoisomerase-targeting anticancer agents.
• To highlight the role of structural and biochemical studies in understanding drug-enzyme interactions.
• To provide a framework for optimizing clinical use of these chemotherapeutics.

Main Methods:

• Review of recent structural and biochemical studies.
• Analysis of cellular pathways involved in DNA damage response.
• Examination of mechanistic similarities between topoisomerase I and II inhibitors.

Main Results:

• Topoisomerase-targeting agents convert target enzymes into DNA-damaging species.
• Structural and biochemical data offer insights into drug action at the enzyme level.
• Cellular responses to topoisomerase-induced DNA damage are crucial for drug efficacy.

Conclusions:

• Understanding topoisomerase targeting mechanisms is key to anticancer drug development.
• Further research can guide the design of improved clinical treatment strategies.
• Optimizing protocols for topoisomerase inhibitors can enhance their therapeutic activity in cancer treatment.